Federman & Sherwood Investigates ZIOPHARM Oncology, Inc. for Possible Violations of Federal Securities Laws

The law firm of Federman & Sherwood has initiated an investigation into ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) with respect to possible violations of federal securities laws.

ZIOPHARM Oncology, Inc. (“ZIOPHARM”) is a biotechnology company, focused on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology and is headquartered in Boston, Massachusetts. Federman & Sherwood’s investigation focuses on disclosures made by ZIOPHARM and whether certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 14, 2016, Laurence Cooper CEO first disclosed that a brain cancer patient in an ongoing clinical trial had died after being treated with the Company's experimental gene therapy, known as Ad-RTS-hIL-12. The FDA has not yet been told about the death. The Company also disclosed the death of a second patient in the ZIOPHARM gene therapy study, for reasons that the Company described as unrelated to Ad-RTS-hIL-12. ZIOPHARM was trying to raise as much as $50 million in a stock offering this week, but the deal was abandoned Thursday night, according to an email sent by bankers from the investment bank Jefferies & Co. to a prospective investor in the deal. That investor forwarded the Jefferies email to TheStreet. On these disclosures, ZIOPHARM stock has declined as much as $1.11, or 19.58%, to $4.56 during intraday trading on July 15, 2016.

If you purchased ZIOPHARM securities and have information to assist in our investigation, or have any questions or concerns regarding this notice or preservation of your rights, please contact our office. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160715005822/en/